Here's an example of an oncology drug (prostate) that was recently fast tracked by the FDA.
It was stopped mid phase 3. It demonstrated a 4.8 month median OS benefit and 5.4mnth PFS. This is a lower benefit than I would have thought to stop the trial early, but due to it's low toxicity it was approved.
http://www.clinicalleader.com/doc.mvc/xtandi-gets-speedy-fda-ok-metastatic-castration-prostate-cancer-0001
benefits of priority review and orphan status
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 1685 | 1 |
View Market Depth
| Last trade - 09.21am 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable